Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio’s Preclinical Candidate Shows Potential
IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targeting leukemia cells while sparing healthy tissue. Experience a potential wider therapeutic window without compromising efficacy.